Overview

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without additional chemotherapy in treating cervical cancer. PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy.

Phase:

Phase 3

Details

Lead Sponsor:

Radiation Therapy Oncology Group

Collaborators:

National Cancer Institute (NCI)
NRG Oncology

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel